Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma
Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S, Rayon-Estrada V, Axisa P, Reeves S, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair F, Kluger H, Hafler D. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nature Immunology 2024, 26: 82-91. PMID: 39609626, DOI: 10.1038/s41590-024-02023-4.Peer-Reviewed Original ResearchCD8+ T cellsAnti-tumor immunityRegulatory T cellsT cellsSubpopulation of CD8+ T cellsCytotoxic CD8+ T cellsHuman CD8+ T cellsTumor antigen-specific CD8Impaired anti-tumor immunityTumor antigen-specificPoor overall survivalTumor rejectionKIR expressionOverall survivalTumor antigensImmune evasionCellular mediatorsHuman cancersCD8MelanomaTumorTranscriptional programsFunctional heterogeneityImmunityPatientsDEPDC5 protects CD8+ T cells from ferroptosis by limiting mTORC1-mediated purine catabolism
Li S, Ouyang X, Sun H, Jin J, Chen Y, Li L, Wang Q, He Y, Wang J, Chen T, Zhong Q, Liang Y, Pierre P, Zou Q, Ye Y, Su B. DEPDC5 protects CD8+ T cells from ferroptosis by limiting mTORC1-mediated purine catabolism. Cell Discovery 2024, 10: 53. PMID: 38763950, PMCID: PMC11102918, DOI: 10.1038/s41421-024-00682-z.Peer-Reviewed Original ResearchCD8+ T cellsPeripheral CD8+ T cellsAnti-tumor immunityT cellsTumor-infiltrating CD8+ T cellsCD8+ T cell homeostasisCD8+ T cell numbersImpaired anti-tumor immunityT cell numbersT-cell protectionT cell homeostasisCancer patient survivalLevels of xanthine oxidasePatient survivalCD8Epilepsy patientsDEPDC5Suppression of ferroptosisMTORC1 signalingFerroptosisMolecular mechanismsImmunityXanthine oxidasePurine catabolismExpression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply